Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

GSK, along with several other drug manufacturing companies, had received a warning letter from the Federal Trade Commission ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

AZ has confirmed that the US regulator issued a complete response letter (CRL) for PT010, a triple therapy for COPD that would compete with GSK’s already-marketed Trelegy. A spokesman for AZ tol ...

GSK GSK-1.51%decrease; red down pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations in the third quarter due ...

GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the group. “​​At this time, we believe there are other areas ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

During the third quarter of 2024, international equities posted strong results: the MSCI ACWI ex USA appreciated 8.1%, ...